Monomethyl Auristatin E, a Potent Cytotoxic Payload for Development of Antibody-Drug Conjugates against Breast Cancer [PDF]
Novelty in Biomedicine, 2017 Background: Breast cancer is a heterogeneous disease characterized by differential responses to targeted and chemotherapeutic agents. Antibody-drug conjugates are one of the promising strategies for the treatment of breast cancer. Monomethyl auristatin E
Meghdad Abdollahpour-alitappeh +9 more
doaj +3 more sources
Payload diversification: a key step in the development of antibody–drug conjugates
Journal of Hematology & Oncology, 2023 Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that currently combines the selectivity of monoclonal antibodies with the potency of a payload consisting of cytotoxic agents. For many years microtubule targeting and DNA-
Louise Conilh +3 more
doaj +2 more sources
Peptide–Drug Conjugates for Targeted Delivery in Hematological Malignancies: From Design Principles to Clinical Application [PDF]
PharmaceuticsHematological malignancies account for over 1.3 million new cases and approximately 700,000 deaths annually. Despite advances in targeted therapies, immunotherapies, and antibody–drug conjugates, relapse, refractory disease, and acquired drug resistance ...
Ningdan Zhou +4 more
doaj +2 more sources
In vitro evaluation of sacituzumab govitecan in non-small cell lung cancer with actionable genomic alterations [PDF]
Translational OncologyPurpose: The TROP2-directed antibody-drug conjugate sacituzumab govitecan (SG) has shown substantial therapeutic benefit in several malignancies; however, preclinical evidence supporting its activity in non-small cell lung cancer (NSCLC) is rare ...
Yerim Park +6 more
doaj +2 more sources
Cancer Medicine, 2019 Antibody‐drug conjugates (ADCs) belong to a promising class of biopharmaceuticals in which target‐killing of tumor cells was achieved by marrying the potency of the cytotoxic payload with the tumor specificity of the antibody.
Baoying Shi +10 more
doaj +2 more sources
Generation of binder-format-payload conjugate-matrices by antibody chain-exchange
Nature CommunicationsThe generation of antibody-drug conjugates with optimal functionality depends on many parameters. These include binder epitope, antibody format, linker composition, conjugation site(s), drug-to-antibody ratio, and conjugation method.
Vedran Vasic +13 more
doaj +2 more sources
EXTH-07. TUMOR-HOMING INDUCED NEURAL STEM CELLS SECRETING A CYTOTOXIC PAYLOAD AS AN ADJUVANT TREATMENT FOR NON-SMALL CELL LUNG CANCER BRAIN METASTASES [PDF]
Neuro-Oncology, 2020 Wulin Jiang +2 more
exaly +1 more source
Antibody-Drug Conjugates Containing Payloads from Marine Origin
Marine Drugs, 2022 Antibody-drug conjugates (ADCs) are an important class of therapeutics for the treatment of cancer. Structurally, an ADC comprises an antibody, which serves as the delivery system, a payload drug that is a potent cytotoxin that kills cancer cells, and a ...
Iván Cheng-Sánchez +4 more
doaj +1 more source
Antibody–Drug Conjugates—A Tutorial Review
Molecules, 2021 Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small ...
Stephanie Baah +2 more
doaj +1 more source
Targeting cancer with antibody-drug conjugates: Promises and challenges
mAbs, 2021 Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S.
Alexis Q. Dean +3 more
doaj +1 more source